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Saro H. Armenian,1 Can-Lan Sun,1 George Mills,1 Jennifer Berano Teh,1 Liton Francisco,1
Jean-Bernard Durand,2 F. Lennie Wong,1 Stephen J. Forman,3 Smita Bhatia1Long-term survival after hematopoietic cell transplantation (HCT) is now an expected outcome. The grow-
ing population of survivors is at risk of developing treatment-related complications, including cardiovascular
disease (CVD). A nested case-controlled design was used to identify clinical and treatment-related risk fac-
tors for development of late (11 years after HCT) CVD. Cases were identified from a cohort of 11-year
survivors who underwent transplantation at City of Hope between 1977 and 2006. Controls (HCT survivors
without CVD) were matched on age, year of HCT, type of HCT, and duration of follow-up. Sixty-three
patients with late CVD were identified, 44 (69.8%) with a coronary artery event and 19 (30.2%) with a cere-
brovascular event. Median age at HCTwas 49.0 years. Median age at onset of late CVDwas 54.0 years; 66.7%
of the affected patients had undergone autologous HCT. Multivariate logistic regression analysis showed
that the presence of multiple cardiovascular risk factors (2 or more of the following: obesity, dyslipidemia,
hypertension, and diabetes) after HCTwas associated with a 5.2-fold increased risk of late CVD (P\.01),
and that pre-HCT chest radiation exposure was associated with a 9.5-fold greater risk of coronary artery
disease (P 5 .03). Pre-HCTexposure to chest radiation and the presence of comorbidities were primarily
responsible for the risk associated with late CVD after HCT. These data form the basis for developing pre-
dictive models for identifying high-risk individuals for targeted surveillance and aggressive management of
comorbidities.
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Hematopoietic cell transplantation (HCT) is the
treatment of choice for many hematologic malignan-
cies. Advances in HCT strategies have contributed to
an incremental improvement in survival of 10% per
decade [1]. This improvement is not enjoyed equally
by all individuals, however. A growing population
of long-term survivors is at risk for developing
treatment-related complications [2-4].
One of the more serious complications is therapy-
related cardiovascular disease (CVD) [5,6]. Previous
reports indicate that cardiovascular events, including1Department of Population Sciences, City of Hope,
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6/j.bbmt.2010.02.021cerebrovascular disease (eg, stroke, transient ischemic
attack [TIA], carotid arterial occlusion, symptomatic
lacunar infarcts), and coronary artery disease (eg,
myocardial infarction, atherosclerotic heart disease,
angina pectoris) are prevalent and often occur earlier
than expected in the general population [3,7,8]. The
cumulative incidence of CVD approaches 23% at 25
years after HCT in certain high-risk populations,
and the incidence appears to increase with time [8].
The risk of CVD is reportedly greatest in recipients
of allogeneic HCT [3]. Such factors such as increasing
age, hypertension, diabetes, dyslipidemia, high body
mass index (BMI), and male sex are known to modify
the risk of CVD in the general population [9,10].
HCT survivors are known to be at an increased
risk for developing diabetes and hypertension, which
potentially can contribute to the risk of CVD in this
population [3]. Finally, HCT recipients are at a 2.3-
to 4.0-fold increased risk of death because of cardiac
causes compared with the general population [11,12].
Taken together, these reports provide evidence for
the fact that CVD is a significant contributor to
post-HCT morbidity and mortality, and that the risk
of CVD potentially could be modified by the presence
of comorbidities.
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sive evaluation of the risk factors associated with the
development of CVD after HCT, and none has
evaluated the role of pre-HCT therapeutic exposure.
The reports describing this outcome are hampered
by small sample size [3,7,8,13], and the contribution
of comorbidities to the risk of CVD among HCT
survivors has not yet been fully explored. In the
current study, we addressed these gaps by evaluating
the role of pre- and post-HCT therapeutic exposures
(ie, chemotherapy and radiation), transplantation-
related conditioning, and post-HCT comorbidities
in the development of CVD in a large cohort of
long-term HCT survivors.METHODS
This study used a nested case-controlled design.
The sampling frame for the cases and controls com-
prised a retrospectively constructed cohort of 3287
consecutive patients who had undergone HCT for
a hematologic malignancy at City of Hope (COH)
between 1977 and 2006 and had survived for at least
1 year. A long-term follow-up (LTFU) form was com-
pleted for each of the 3287 patients in this cohort.
Information collected on the LTFU form included
demographic data, disease status, medication, hospi-
talization, and post-HCT complications, including
CVD, and details regarding graft-versus-host disease
(GVHD). This information was merged with data
from an institutional database on HCT-related expo-
sures, such as conditioning and GVHD prophylaxis/
treatment. The LTFU form captured information re-
garding post-HCT complications beginning at 1 year
posttransplantation through the date of last contact.
Medical records maintained at COH were the pri-
mary source of data for completing the LTFU forms.
If a patient’s last medical visit was not recent, or if there
were any unexpected gaps in a patient’s history within
the follow-up period of interest, then a standard proto-
col was used to identify and contact any physicians
treating the patient outside COH to obtain pertinent
information. If the physician was not available or was
unable to provide recent information, then the patient
was called directly. This method of follow-up ensured
that information regarding CVD was captured in an
uninterrupted fashion from 1 year post-HCT to the
date of last contact with a health care provider. The
COHHuman Subjects Committee approved the study
protocol. Informed consent was provided in accor-
dance with the Declaration of Helsinki.
To be eligible for consideration as a case, a patient
had to have developed CVD (coronary artery or cere-
brovascular disease) 1 or more years after HCT. Con-
trols (between 1 and 3) were selected at random from
the same cohort and matched to cases for age atHCT (6 5 years), year of HCT (6 2 years), donor
source (autologous vs allogeneic), and duration of
follow-up (control follow-up exceeded matched case
follow-up).Exposure Variables
For both cases and controls, medical records from
COH and other institutions (if indicated) were used to
abstract clinical and therapeutic information during
the pre-HCT, conditioning, and post-HCT periods.
The following data were collected: demographic infor-
mation, disease characteristics, pre-HCT therapeutic
exposures (chemotherapy: cumulative dose per square
meter body surface area; radiation therapy: total dose,
field, and dose per fraction), conditioning regimen
(chemotherapeutic agents; total body irradiation
[TBI]: number of fractions and total dose).
Therapeutic exposures were summarized for cases
and controls. An anthracycline cardiotoxicity risk
score [14] was calculated by multiplying the cumula-
tive dose of each anthracycline (ie, doxorubicin, dau-
norubicin, epirubicin, idarubicin, and mitoxantrone)
by a factor reflecting the cardiotoxic potential of
each drug and then summing the individual scores.
A cumulative alkylating agent dose was calculated by
multiplying the cumulative dose of each alkylating
agent (ie, cyclophosphamide[Cy], procarbazine, ifosfa-
mide, dacarbazine, busulfan, carmustine, lomustine,
and melphalan) by a factor reflecting its acute hemato-
toxic potential and again summing the individual
scores [15,16] (see Supplement, Table 1). Chest
radiation included mantle (standard and modified),
mediastinal, and lung radiation; neck radiation broadly
included cervical, parotid, nasopharynx, and extended
mantle radiation.Cardiovascular Risk Factors
Comorbidities developing before or after HCT
were identified through medical record abstraction.
A patient’s comorbidities were captured if diagnosed
by the treating physician and/or if the patient was task-
ing medications for their management. To be consid-
ered a post-HCT event, a comorbidity had to be
diagnosed after the HCT, but before the onset of
CVD. Furthermore, the comorbidity had to be active
at the time of the event (cases) or for a comparable pe-
riod of follow-up (controls).
Separate pre-HCT and post-HCT cardiovascular
risk scores were calculated by assigning a point for
each of the following comorbidities, all of which are
well-recognized risk factors for CVD: hypertension,
dyslipidemia, diabetes, and obesity (BMI .30 kg/m2
at HCT) [7,10]. Patients with a cardiovascular risk
score $2 were considered at high risk for CVD
[7,10,17].
Table 1. Characteristics of the Patient Population and Pre-
HCT Exposure
Characteristic
Cases
(n 5 63)*
Controls
(n 5 186)*
P
Value
Age at initial diagnosis, years,
mean (SD)
47.8 (13.0) 47.3 (12.5) .69
Male sex, n (%) 43 (68.3) 96 (51.6) .03
Ethnicity/race, n (%)
Non-Hispanic white 47 (74.6) 119 (64.0) .14
Others 16 (25.3) 67 (36.0)
Diagnosis, n (%)†
Lymphoma 27 (42.9) 67 (36.0) .31
Non-Hodgkin lymphoma 23 (36.5) 57 (30.6)
Hodgkin lymphoma 4 (6.3) 10 (5.4)
Nonlymphoma 36 (57.1) 119 (64.0)
Multiple myeloma 12 (19.0) 43 (23.1)
Acute lymphoblastic leukemia 4 (6.3) 11 (5.9)
Acute myelogenous leukemia 10 (15.9) 33 (17.7)
Chronic myelogenous leukemia 9 (14.3) 16 (8.6)
Other 1 (1.6) 16 (8.6)
Pre-HCT comorbidity, No. (%)
Smoking, ever 31 (49.2) 75 (40.3) .27
Hypertension 16 (25.4) 24 (12.9) .03
Dyslipidemia 6 (9.5) 12 (6.5) .41
Diabetes 3 (4.8) 9 (4.8) .99
Pre-HCT therapy
Anthracycline, mg/m2, mean (SD) 205.1 (140.9) 177.8 (139.4) .18
Alkylating agent, g/m2, mean (SD) 4.2 (7.8) 3.2 (9.6) .43
Cisplatin, mg/m2, mean (SD) 60.0 (139.5) 48.4 (121.1) .38
Cranial radiation, n (%) 2 (3.2) 7 (3.8) .84
Neck radiation, n (%) 2 (3.2) 6 (3.2) .99
Chest radiation, n (%) 5 (7.9) 6 (3.2) .17
SD indicates standard deviation;HCT, hematopoietic cell transplantation.
*Group matching criteria included age at HCT (65 years), type of HCT
(autologous vs allogeneic), year of HCT (6 2 years), and duration of
follow-up.
†Analyzed as lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma)
versus nonlymphoma (multiple myeloma, acute lymphocytic leukemia,
acute myelogenous leukemia, chronic myelogenous leukemia, and
other).
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Late CVD events were defined as cardiovascular
events developing 11 years after HCT and were clas-
sified as coronary artery disease (ie, myocardial infarc-
tion, angina pectoris, or symptomatic atherosclerotic
heart disease [coronary artery narrowing .50%]) or
cerebrovascular disease (ie, stroke, TIA, symptomatic
lacunar infarct, or symptomatic carotid artery occlu-
sion [.50% narrowing] necessitating surgical inter-
vention) in accordance with the American College of
Cardiology’s (ACC) established case definitions and
clinical data standards for coronary artery and cerebro-
vascular disease [18-20]. Cerebrovascular events were
excluded if they resulted from thrombocytopenia
or clotting factor deficiency or were from central
nervous system (CNS) trauma, infection, or active
CNS disease.Statistical Analysis
Cases and controls were compared in terms of
demographics, pre-HCT therapeutic exposures,
HCT-related conditioning, and pre- and post-HCT
cardiovascular risk factors, using conditional logisticregression for categorical variables and linear regres-
sion adjusting for matching sets for continuous
variables. For the purpose of this analysis, primary
diagnoses were categorized into 2 groups: lymphoma
(ie, non-Hodgkin lymphoma [NHL] and Hodgkin
lymphoma [HL]) and nonlymphoma (ie, multiple my-
eloma, acute lymphoblastic leukemia, acute myeloge-
nous leukemia, chronic myelogenous leukemia, and
other diagnoses).
Multivariate conditional logistic regression was
used to identify variables that were significantly and
independently associated with CVD after HCT. Vari-
ables included were those significantly associated
with CVD on univariate analysis, as well as those
considered to have an impact on the clinical outcome
but that were not part of the matching criteria. The re-
gression model included sex, ethnicity (non-Hispanic
white vs other), smoking history (never vs ever),
diagnosis (lymphoma vs nonlymphoma), pre- and
post-HCT cardiovascular risk factors (dichotomized
as \2 vs $2 conditions), conditioning with chemo-
therapeutic agents (no vs yes), TBI (no vs yes), and
age at diagnosis (continuous variable). Separate regres-
sion models also were created for coronary artery and
cerebrovascular disease to identify risk factors that
might be unique to these outcomes. For the coronary
artery disease model, pre-HCT chest radiation expo-
sure was added to the model; for the cerebrovascular
disease model, pre-HCT head and neck radiation
exposure were added. An alpha level of\.05 was con-
sidered significant. Statistical analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC).RESULTS
Sixty-three cases with late CVD and 186 matched
controls were included in the analysis. Sixty-one cases
(97%) had 3 matched controls. The median follow-up
after HCT was 7.3 years (range, 1.3-29.8 years) for
cases and 8.2 years (range, 1.4-30.4 years) for controls;
37% of cases and controls were 101-year survivors.
Patient Characteristics
Table 1 summarizes the clinical characteristics of
cases and controls. Cases were significantly more likely
to be male (68.3% vs 51.6%; P 5 .03). There were no
significant differences between cases and controls with
respect to age at diagnosis, race/ethnicity, or underly-
ing diagnoses. Among allogeneic HCT recipients,
there were no differences between cases and controls
with respect to the prevalence of acute GVHD or of
previous or active chronic GVHD (data not shown).
Therapeutic Exposures
The interval between the diagnosis of primary
disease and HCT was comparable in the cases and
Table 2. HCT Conditioning Regimens and Post-HCT
Outcomes
Characteristic
Cases
(n 5 63)*
Controls
(n 5 186)*
P
Value
Age at HCT, years, mean (SD) 49.6 (13.0) 48.8 (12.3)
Autologous donor source, n (%) 42 (66.7) 123 (66.1)
Time from diagnosis to HCT, years,
mean (SD)
1.8 (3.6) 1.5 (1.7) .24
Body mass index at HCT, kg/m2,
mean (SD)
28.5 (6.4) 26.6 (5.0) .01
Conditioning regimen
Cyclophosphamide 45 (71.4) 112 (60.2) .04
Etoposide 33 (52.4) 99 (53.2) .79
TBI 34 (54.0) 98 (52.7) .78
Melphalan 15 (23.8) 60 (32.3) .09
Carmustine 10 (15.9) 22 (11.8) .46
Busulfan 8 (12.7) 24 (12.9) .99
Post-HCT comorbidities
Hypertension 23 (36.5) 35 (18.8) <.01
Dyslipidemia 21 (33.3) 28 (15.1) <.01
Diabetes 13 (20.6) 20 (10.8) .05
Cardiovascular risk†
<2 conditions 50 (84.1) 169 (91.9) <.01
$2 conditions 10 (15.9) 15 (8.1)
SD indicates standard deviation; HCT, hematopoietic cell transplanta-
tion; TBI, total body irradiation.
*Group matching criteria included: age at HCT (65 years), type of HCT
(autologous vs allogeneic), year of HCT (62 years), and duration of
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There were no significant differences between cases
and controls with respect to cumulative exposure to
anthracycline, alkylating agents, or cisplatin, or to
exposure to cranial, neck, or chest radiation. When
data were analyzed separately for coronary artery and
cerebrovascular events, pre-HCT exposure to chest
radiation was more prevalent in cases with coronary
artery disease compared with controls (11.4% vs
2.3%; P5 .01); median chest radiation dose was equiv-
alent in the 2 groups (40 Gy [range, 24-42 Gy] vs 40
Gy [range, 36-40 Gy]). There were no significant
differences in the proportion of patients treated with
cranial (8.8% vs 5.3%; P 5 .62) or neck (5.3% vs
3.5%; P 5 .73) radiation between cases with cerebro-
vascular disease and matched controls.
Cy (63.1%), etoposide (53.0%), and TBI (53.0%)
were the most commonly used conditioning agents.
Cases were significantly more likely than controls to
have received Cy as part of their conditioning regimen
(71.4% vs 60.2%; P 5 .04) (Table 2). There were no
significant differences between the 2 groups with
respect to all other conditioning exposures.follow-up.
†Conditions included hypertension, dyslipidemia, diabetes, and obesity
(BMI >30 kg/m2) at HCTCardiovascular Risk Factors
Pre-HCT Cardiovascular Risk Factors
Cases were significantly more likely than controls
to have been diagnosed with hypertension before
HCT (25.4% vs 12.9%; P 5 .03) and to have a higher
BMI at the time of HCT (28.5 kg/m2 vs 26.6 kg/m2;
P 5 .01). There were no significant differences
between the 2 groups in the prevalence of other cardio-
vascular risk factors before HCT.
Post-HCT Cardiovascular Risk Factors
With equivalent follow-up, cases were significantly
more likely than controls to have hypertension (36.5%
vs 18.8%; P\.01), dyslipidemia (33.3 vs 15.1; P\.01),
and diabetes (20.6 vs 10.8; P 5 .05) (Table 2). Cases
also were significantly more likely than controls to
have multiple post-HCT cardiovascular risk factors
(15.9 vs 8.1; P \.01). There were no differences
between the 2 groups with respect to prevalence of
immunosuppressive therapy at the time of cardiovas-
cular risk assessment for allogeneic HCT recipients
(52.4% vs 44.4%; P 5 .53).Clinical Presentation of Late CVD
Of the 63 cases with late CVD, 44 (69.8%)
presented with clinically documented coronary artery
disease (myocardial infarction, n5 32; atherosclerotic
heart disease, n 5 9; angina pectoris, n 5 3), and 19
(30.2%) presented with cerebrovascular disease (TIA,
n5 9; stroke, n5 7; symptomatic carotid artery steno-
sis, n 5 3). All met the clinical diagnostic criteria inaccordance with the ACC’s established case definitions
and clinical data standards for coronary artery and
cerebrovascular disease [18-20]. The median time to
CVD was 4.0 years after HCT (range, 1.15-19.4
years), and the median age at presentation was 54.0
years (range, 25.0-82.4 years). None of these cases
exhibited clinical evidence of CVD during the first
year after HCT.
Of the 63 patients with late CVD, 34 have died.
Overall survival following diagnosis of CVD (cases)
and comparable follow-up (controls) was significantly
worse for cases compared with controls (52.4% vs
80.6% at 5 years; P\ .01). For cases, the most com-
mon causes of mortality were relapse/progression
of primary disease (34.6%), cardiovascular events
(30.7%), and infection (15.0%). For controls, re-
lapse/progression of primary disease (69.8%) and
infection (12.4%) were the most common causes of
death.Risk Factors for Late CVD
As shown in Table 3, multivariate conditional
logistic regression revealed that the presence of 2 or
more of the 4 targeted cardiovascular risk factors (ie,
obesity, dyslipidemia, hypertension, and diabetes)
was significantly and independently associated with
a .5-fold (odds ratio [OR], 5.2; P \ .01) increased
risk of CVD. Furthermore, conditioning with Cy
trended toward an increased risk for late CVD (OR,
2.5; P 5.06).
Table 3. MultivariateAnalysis of Risk FactorsAssociatedwith
Late CVD
Risk Factor OR 95% CI P Value
Sex
Female 1.0
Male 1.6 0.80-3.21 .18
Ethnicity
Others 1.0
Non-Hispanic white 1.8 0.87-3.68 .12
Age at diagnosis 0.96-1.17 .23
Smoking
Never 1.0
Ever 1.3 0.67-2.38 .46
Diagnosis*
Nonlymphoma 1.0
Lymphoma 0.8 0.31-1.97 .60
Pre-HCT cardiovascular
risk factors
<2 conditions 1.0
$2 conditions 0.8 0.25-2.65 .74
Conditioning chemotherapy
No cyclophosphamide 1.0
Cyclophosphamide 2.5 0.94-6.66 .06
TBI
No TBI 1.0
TBI 1.0 0.47-2.24 .94
Post-HCT cardiovascular
risk factors
<2 conditions 1.0
$2 conditions 5.2 2.14-12.83 <.01
HCT indicates hematopoietic cell transplantation; TBI, total body
irradiation.
*Analyzed as lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma)
versus nonlymphoma (multiple myeloma, acute lymphoblastic leukemia,
acute myelogeous leukemia, chronic myelogenous leukemia, and other).
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Multivariate analysis restricted to cases with coro-
nary artery disease and their matched controls revealed
that pre-HCT exposure to chest radiation (OR, 9.5;
P 5 .03) and the presence of multiple post-HCT
cardiovascular risk factors (OR, 4.8; P \.01) were
associated with increased risk.
Cerebrovascular Disease
The presence of multiple post-HCT cardiovascu-
lar risk factors was associated with a 19.5-fold risk of
late cerebrovascular disease (OR, 19.5; P5 .02). Expo-
sure to neck radiation (OR, 0.9; P 5 .97) and cranial
radiation (OR, 0.1; P 5 .20) were not associated with
increased risk.DISCUSSION
The overall goal of this study was to conduct com-
prehensive evaluation of the impact of therapeutic ex-
posures (pre-HCT, HCT-related conditioning, and
post-HCT) and cardiovascular risk factors on the
risk of late CVD in long-term survivors of HCT. To
date, few studies have evaluated late-onset coronary
artery events or stroke, in part because of the length
and thoroughness of follow-up necessary to documentthese outcomes. Our study is the first to incorporate
pre-HCT therapeutic exposures, conditioning, and
post-HCT exposures and comorbidities to create
a comprehensive risk profile for late CVD. We found
that, other than a 9.5-fold increased risk of coronary
artery disease with pre-HCT exposure to chest radia-
tion, the risk of late-onset CVD is related primarily
to cardiovascular risk factors developing after HCT.
It is increasingly recognized that atherosclerosis is
an inflammatory process, with endothelial injury oc-
curring several years before clinically evident CVD de-
velops [21-23]. Whereas endothelial injury can occur
acutely after treatment with high-dose alkylator- or
platinum-based chemotherapy, long-term follow-up
of non-HCT populations, such as HL [24], breast can-
cer [25], and testicular cancer [26] survivors, has shown
that the risk of late-onset CVD is due primarily to
chest radiation exposure, not to systemic chemother-
apy. Radiation-induced vascular injury is characterized
by endothelial cell proliferation, intimal thickening,
medial scarring, lipid deposits, and adventitial fibrosis
[27]; this process forms the basis for the ensuing ath-
erogenesis and plaque formation in these long-
term survivors [27]. In non-HCT populations, the
risk of mortality frommyocardial infarction after chest
radiation exposure ranges from 2.2- to 7.2-fold over
that of age- and sex-matched controls [28]; individuals
at highest risk are those treated at age .21 years,
with higher doses of radiation (.40 Gy), and those
treated during an earlier era (\1985) [24,27,28]. In
the current study, we found a 9.5-fold increased risk
of coronary artery disease in survivors treated with
chest radiation, after adjustment for demographics,
treatment era, other therapeutic (pre-HCT chemo-
therapy, conditioning) exposures, and cardiovascular
risk factors. Unlike previous reports [29,30], we
were unable to demonstrate an association between
cerebrovascular disease and cranial or neck radiation.
Well-established cardiovascular risk factors, such
as insulin resistance with compensatory hyperinsuline-
mia, impaired glucose tolerance, hypertriglyceridemia,
hypertension, and central obesity, are being increas-
ingly reported after HCT [3,31-34]. Dyslipidemia,
glucose intolerance, and hypertension can be con-
sequences of prolonged immunosuppressive therapy
after allogeneic HCT, exposure to TBI, or other
conditions, such as growth hormone deficiency or
hypothyroidism [6]. In conventionally treated cancer
populations, cardiovascular risk factors are known to
modify the risk of CVD [24-26]. The study of
Dorresteijn et al. [35] was one of the first to report
an increased risk of CVD in long-term cancer survi-
vors, demonstrating a 12-fold increased risk of stroke
in head and neck cancer survivors with diabetes or
hypertension compared with survivors without these
risk factors, and the magnitude of risk increased with
increasing duration of follow-up. Later studies in HL
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confirmed that certain chronic health conditions,
such as hypertension, diabetes, and dyslipidemia, sig-
nificantly increase the risk of CVD, even after adjust-
ment for well-recognized demographic (age, sex),
lifestyle (smoking history), and therapeutic (ionizing
radiation) risk factors. These findings have formed
the basis for current recommendations for screening
and cardiovascular risk reduction in childhood and
adult-onset cancer survivors [28,37,38].
Few studies have explored this association in HCT
survivors, however. A recent report found a greater risk
of CVD in allogeneic HCT recipients and in those
withmultiple cardiovascular risk factors [8]. In another
study limited to allogeneic HCT recipients, older age
at HCT and having multiple cardiovascular risk fac-
tors were the only significant predicators of self-
reported late cardiovascular events [7]. In the current
study, HCT survivors with CVD were significantly
more likely to have multiple cardiovascular risk fac-
tors, resulting in a .5-fold increased risk of CVD. In
fact, having a high cardiovascular risk score was associ-
ated with a 20-fold increased risk of cerebrovascular
complications, such as stroke or TIA, after HCT.
High-dose Cy is commonly used as part of condi-
tioning regimens for HCT. Cardiotoxicity associated
with high-dose Cy is typically acute and dose-
dependent, and ranges from asymptomatic electrocar-
diographic changes to pancarditis and congestive heart
failure [6,39]. Whether subclinical myocardial injury
sustained during conditioning contributes to the
acceleration of atherosclerotic disease after HCT is
unclear. Preliminary studies suggest that patients
treated with high-dose Cy have higher numbers of
circulating endothelial cells immediately after condi-
tioning [40,41]. These endothelial cells may reflect
disruption of the microvascular bed, leading to
accelerated thrombus formation [40,41]. The role of
Cy-induced endothelial injury in initiating clinically
significant CVD years after HCT is not well defined.
In the current study, conditioning with cyclophospha-
mide was associated with a 2.5-fold higher risk
of CVD, an association that approached statistical
significance.
Any retrospective review of medical records is lim-
ited by the amount of information available for review.
As such, we were not able to reliably ascertain informa-
tion regarding other cardiovascular risk factors, such
as currency of smoking or pack-years of tobacco
exposure, as well as details regarding physical activity.
However, the prevalence of any smoking was equiva-
lent to previous reports from similar populations
[24,30] and was included in the final multivariate
analysismodel.Other studies using self-reported infor-
mation from a similar population have demonstrated
that the large majority of HCT survivors quit smoking
after HCT, with\15% reporting current tobacco use[7,42]. The cases included in this study had clinically
overt coronary artery or cerebrovascular disease. No
individuals who may have had asymptomatic CVD
were included. The focus of this study was on
developing a deeper understanding of the impact of
HCT-related exposures and comorbidities on the
development of clinically overt cardiovascular events,
and asymptomatic CVD does not fit this definition.
In summary, our findings indicate that pre-HCT
exposure to chest radiation and the development of
multiple cardiovascular risk factors post-HCT are pri-
marily responsible for the high risk of CVD in HCT
survivors. Although it appears that conditioning with
high-dose Cy might have contributed to an increased
risk,more studies are needed to evaluate the role of con-
ditioning exposures in initiating clinically significant
CVD in the post-HCT setting. These data form the
basis for developing predictive models for identifying
high-risk individuals to conduct targeted surveillance,
as well as to develop preventive strategies in the form
of aggressive management of comorbidities.ACKNOWLEDGMENTS
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